Nanoparticles for preventing peri/post-menopausal bone loss and/or obesity
Nanoparticles and formulations for preventing or reducing peri-/post-menopausal bone loss and/or obesity in a subject are disclosed. The nanoparticles contain a cage, such as a zeolitic imidazolate framework (“ZIF”), a surface modifying agent, a targeting ligand, and an active agent. The surface modifying agent is attached to the outer surface of the cage and the targeting ligand is exposed to the surrounding environment. The active agent is encapsulated in the cage. The targeting ligand binds to a reproductive hormone or a receptor of a reproductive hormone. The active agent can be a ribosome inactivating protein, an apoptosis inducer, a hormone, a receptor ligand, or a nucleic acid, or a combination thereof, that inactivate ribosomes of gonadotroph cells and/or prevent or reduce secretion of follicle-stimulating hormones in the subject. Uses for formulations incorporating the nanoparticles for preventing or reducing peri-/post-menopausal bone loss and/or obesity in a subject are also disclosed.
1. A pharmaceutical formulation for preventing or reducing peri-/post-menopausal bone loss and/or obesity in a subject comprising
(a) a plurality of nanoparticles, wherein the nanoparticles comprise
a cage,
a surface modifying agent,
a targeting ligand, and
an active agent,
wherein the cage is a zeolitic imidazolate framework (“ZIF”)
wherein the surface modifying agent is attached to an outer surface of the cage and wherein the targeting ligand is exposed to a surrounding environment,
wherein the targeting ligand is a gonadotropin-releasing hormone (“GnRH”) receptor agonist, or a follicle stimulating hormone (“FSH”) receptor agonist, or a luteinizing hormone (“LH”) receptor agonist, or a combination thereof, and
wherein the active agent is encapsulated in the cage; and
(b) a pharmaceutically acceptable carrier and/or excipient.
2. The pharmaceutical formulation of claim 1 , wherein the pharmaceutical formulation comprises an effective amount of the nanoparticles to reduce or prevent bone loss, reduce body weight, reduce percentage of fat, reduce body mass index (BMI), and/or decrease leptin level in the blood of a subject in need thereof.
3. The pharmaceutical formulation of claim 2 , wherein the effective amount of the nanoparticles is effective to reduce the body weight, reduce the percentage of fat, and/or reduce the body mass index (“BMI”) of the subject by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, or at least 30% compared to the body weight, the percentage of fat, and/or the BMI of the subject before treatment.
4. The pharmaceutical formulation of claim 2 , wherein the effective amount of the nanoparticles is effective to reduce bone loss in the subject as shown by an increase or decrease of an osteoporosis biomarker level in the blood of the subject by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, or at least 30% compared to the osteoporosis biomarker level in the blood of the subject before treatment.
5. The pharmaceutical formulation of claim 2 , wherein the effective amount of the nanoparticles is effective to decrease the leptin level in the blood of the subject by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, or at least 30% compared to the leptin level in the blood of the subject before treatment.
6. The pharmaceutical formulation of claim 1 , wherein the pharmaceutical formulation is in a form suitable for intramuscular administration, intravenous administration, intraperitoneal administration, or subcutaneous administration, or a combination thereof.
7. A method for reducing peri-/post-menopausal bone loss and/or obesity in a subject in need thereof comprising
(i) administering to the subject the pharmaceutical formulation of claim 1 , wherein step (i) occurs one or more times.
8. The pharmaceutical formulation of claim 1 , wherein the ZIF comprises a metal ion selected from the group consisting of Zn + , Zn 2+ , Pd 2+ , Pd 4+ , Pt 2+ , Pt 4+ , Ni + , Ni 2+ , Ni 3+ , Mn 2+ , Mn 3+ , Mn 4+ , Mn 6+ , Mn 7+ , Co 2+ , Co 3+ , Cu 2+ , Cd 2+ , Fe 2+ , Fe 3+ , and Ti 4+ .
9. The pharmaceutical formulation of claim 1 , wherein the ZIF comprises imidazolate functionalized with amine, hydroxyl, thiol, aldehyde, or carboxyl, or a combination thereof.
10. The pharmaceutical formulation of claim 1 , wherein the ZIF is ZIF-2, ZIF-3, ZIF-4, ZIF-8, ZIF-10, ZIF-11, ZIF-12, ZIF-14, ZIF-20, ZIF-21, ZIF-60, ZIF-61, ZIF-62, ZIF-64, ZIF-65, ZIF-66, ZIF-67, ZIF-68, ZIF-69, ZIF-70, ZIF-71, ZIF-72, ZIF-73, ZIF-74, ZIF-75, ZIF-76, ZIF-77, ZIF-78, ZIF-81, ZIF-82, ZIF-90, ZIF-91, ZIF-92, ZIF-95, or ZIF-100.
11. The pharmaceutical formulation of claim 1 , wherein at least 20 wt %, at least 25 wt %, at least 30 wt %, at least 35 wt %, at least 40 wt %, at least 45 wt %, at least 50 wt %, at least 55 wt %, at least 60 wt %, at least 65 wt %, at least 70 wt %, at least 75 wt %, at least 80 wt %, at least 85 wt %, at least 90 wt %, at least 95 wt %, in a range from 20 wt % to 100 wt %, from 30 wt % to 100 wt %, or from 40 wt % to 100 wt % of the surface modifying agent is conjugated to the targeting ligand.
12. The pharmaceutical formulation of claim 1 , wherein the end of the surface modifying agent that is attached to the cage comprises a chemical moiety containing one or more negative charges.
13. The pharmaceutical formulation of claim 12 , wherein the chemical moiety is folate, L-methylfolate, or glutamate, or a combination thereof.
14. The pharmaceutical formulation of claim 1 , wherein the surface modifying agent comprises a polymer backbone selected from the group consisting of polyalkylene glycol, polylactic acid, polyglycolic acid, poly(lactic-co-glycolic acid), polyanhydrides, poly(ortho) esters, polyurethanes, poly(butyric acid), poly(valeric acid), poly(lactide-coaprolactone), and polyethylenimine, and a copolymer thereof.
15. The pharmaceutical formulation of claim 14 , wherein the polymer backbone has a molecular weight in a range from about 1 kDa to about 10 kDa, from about 2 kDa to about 10 kDa, from about 3 kDa to about 10 kDa, from about 4 kDa to about 10 kDa, from about 1 kDa to about 9 kDa, from about 2 kDa to about 9 kDa, from about 3 kDa to about 9 kDa, from about 4 kDa to about 9 kDa, from about 1 kDa to about 8 kDa, from about 2 kDa to about 8 kDa, from about 3 kDa to about 8 kDa, from about 4 kDa to about 8 kDa, from about 1 kDa to about 7 kDa, from about 2 kDa to about 7 kDa, from about 3 kDa to about 7 kDa, from about 4 kDa to about 7 kDa, from about 1 kDa to about 6 kDa, from about 2 kDa to about 6 kDa, from about 3 kDa to about 6 kDa, or from about 4 kDa to about 6 kDa.
16. The pharmaceutical formulation of claim 1 , having an average diameter in a range from about 10 nm to about 100 nm, from about 10 nm to about 90 nm, from about 10 nm to about 80 nm, from about 20 nm to about 100 nm, from about 20 nm to about 90 nm, from about 20 nm to about 80 nm, from about 30 nm to about 100 nm, from about 30 nm to about 90 nm, or from about 30 nm to about 80 nm.
17. The pharmaceutical formulation of claim 1 , wherein the surface density of the surface modifying agent (“SMA”) on the surface of the nanoparticle is at least 1 SMA/nm 2 , at least 5 SMA/nm 2 , at least 7 SMA/nm 2 , at least 10 SMA/nm 2 , at least 15 SMA/nm 2 , at least 20 SMA/nm 2 , at least 25 SMA/nm 2 , at least 30 SMA/nm 2 , at least 35 SMA/nm 2 , at least 40 SMA/nm 2 , at least 45 SMA/nm 2 , or at least 50 SMA/nm 2 .
18. The pharmaceutical formulation of claim 1 , wherein the active agent is a ribosome inactivating protein, an apoptosis inducer, a hormone, a receptor ligand, or a nucleic acid, or a combination thereof.
19. The pharmaceutical formulation of claim 14 , wherein the polymer backbone of the surface modifying agent is polyethylene glycol.